Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Subscribe To Our Newsletter & Stay Updated
